Levobupivacaine 0.5% + epinephrin 1/200000 — Competitive Intelligence Brief

Levobupivacaine 0.5% + epinephrin 1/200000 (Levobupivacaine 0.5% + epinephrin 1/200000) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with vasoconstrictor. Area: Anesthesia.

marketed Local anesthetic with vasoconstrictor Voltage-gated sodium channels; alpha-adrenergic receptors Anesthesia Small molecule

Target snapshot

Levobupivacaine 0.5% + epinephrin 1/200000 (Levobupivacaine 0.5% + epinephrin 1/200000) — University Hospital, Antwerp. Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levobupivacaine 0.5% + epinephrin 1/200000 TARGET	Levobupivacaine 0.5% + epinephrin 1/200000	University Hospital, Antwerp	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-adrenergic receptors
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
lidocaine + epinephrine 1:100,000	lidocaine + epinephrine 1:100,000	Weill Medical College of Cornell University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
tetracaine HCl and oxymetazoline HCL	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
Tumescent Solution with dilute epinephrine	Tumescent Solution with dilute epinephrine	University of Wisconsin, Madison	marketed	Local anesthetic with vasoconstrictor
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with vasoconstrictor class)

1. Ankara Yildirim Beyazıt University · 1 drug in this class
2. Health Sciences North Research Institute · 1 drug in this class
3. Ohio State University · 1 drug in this class
4. Pontificia Universidad Catolica de Chile · 1 drug in this class
5. University Hospital, Antwerp · 1 drug in this class
6. University of Wisconsin, Madison · 1 drug in this class
7. Vrije Universiteit Brussel · 1 drug in this class
8. Wahba bakhet · 1 drug in this class
9. Weill Medical College of Cornell University · 1 drug in this class